Onco Actu du 4 avril 2016

	3.1 Tabac
Indian cigarette makers halt production over health warning rules [Reuters] The Tobacco Institute of India (TII) said the industry was concerned over potential violation of health warning rules by continuing production, adding that the production halt would cost the industry $53 million a day.
	5. Traitements
Microneedles patch into skin cancer [Chemical & Engineering News] Patch allows for targeted delivery of nanoparticles loaded with promising drug.
	5.2 Pharma
Array Bio stops study testing drug for ovarian cancer [Reuters] The drug is also being tested for use in patients with different forms of skin cancer, BRAF-mutant melanoma and NRAS-mutant melanoma.
	5.3.4 Traitements - AMM (FDA, EMA)
New treatment for patients with multiple myeloma [EMA] The CHMP’s recommendation is based on two studies. In one study of 106 patients receiving Darzalex, tumours shrank or could no longer be seen in 29% of the patients over an average of 7.4 months. In the second study of 42 patients receiving Darzalex, tumours shrank or could no longer be seen in 36% of patients.
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) for Treatment of Advanced Melanoma [BMS] First combination of two Immuno-Oncology agents in advanced melanoma to receive positive CHMP opinion, based on efficacy and safety data from two trials, CheckMate -067 and CheckMate -069.
Halaven [EMA] The CHMP adopted a new indication as follows: "treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease".
Opdivo [EMA] “Opdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see section 4.4 and 5.1).”
Darzalex [EMA] Darzalex should be administered by a healthcare professional, in an environment where resuscitation facilities are available.
EU recommends conditional approval for J&J's blood cancer drug [Reuters] The European Medicines Agency's (EMA) recommendation applies to the use of the antibody treatment in adults who have already undergone standard treatments for multiple myeloma.
	5.4 Traitements - Economie
Is pharma industry too meek on pricing? [Health Business Blog] So while PhRMA may complain about requests for “transparency” on R&D spending –and I agree this information is worthless, not to mention time consuming and expensive to collect– the industry brought the issue on itself.
	6.8 Communication
Vegetarianism doesn’t cause cancer, despite what many news outlets reported this week -[HealthNewsReview] The researchers came up with an interesting hypothesis about which there is not yet any data, which concerns a conflicted field of science. I think it’s fair to say the news release implied far more than the paper actually found.